First Reported Case in Romania of a Successfully Treated Severe COVID-19 in a Kidney Transplant Recipient: A Focus on Acute Kidney Injury

• Published in: Case reports in nephrology and dialysis Vol. 10; no. 3; pp. 174 - 179
• Main Authors: Tosa, Flaviu, Manaila, Roxana, Elec, Alina, Moisoiu, Tudor, Ghervan, Liviu, Elec, Florin
• Format: Journal Article
• Language: English
• Published: Basel, Switzerland S. Karger AG 01.09.2020; Karger Publishers
• Subjects: acute kidney injury; Blood; Case reports; coronavirus disease 2019; Coronaviruses; COVID-19; Creatinine; Cytokine storm; Dehydrogenases; Diarrhea; Drug dosages; Fungal infections; Hypokalemia; Hyponatremia; Intensive care; kidney transplantation; Kidney transplants; Laboratories; Oxygen therapy; Plasma; Pneumonia; Polyuria; Pulmonology; Respiratory distress syndrome; Severe acute respiratory syndrome coronavirus 2; Single Case; Thrombocytopenia; Urine; Ventilators; Coronavirus disease 2019; Acute kidney injury; Kidney transplantation
• ISSN: 2296-9705; 2296-9705
• DOI: 10.1159/000512606

As coronavirus disease 2019 (COVID-19) caused by the novel virus SARS-CoV-2 is expanding worldwide, kidney involvement seems to be part of the spectrum of its effects. Moreover, the prognosis of the disease seems to be worse in immunocompromised patients when compared to the general population, with 4–5 times higher mortality rates. However, the overall impact on long-term function of the kidney graft is unknown. We report on a case of a 46-year-old kidney transplant recipient who was successfully treated for severe COVID-19 pneumonia. The clinical course was complicated by transient acute kidney injury, most likely due to tubulo-interstitial involvement, with return to the baseline of the creatinine level by the time of discharge. We discuss the characteristics and differential diagnosis of acute kidney injury, as well as management of immunosuppression in connection with overall clinical status and evolution of kidney function. The case is illustrative for dilemmas that transplant professionals may face in the absence of evidence-based, efficient COVID-19 therapy. The risk-benefit balance of the yet to be approved treatment strategies may be weighed differently in organ transplant recipients owing to their immunocompromised status and potential drug interactions with immunosuppressive therapy.